clinical trial · NCT06132256
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary FibrosisAxatilimabPlacebo
brief summary
The study will evaluate the efficacy and safety of axatilimab in participants with IPF.
started
Dec 11, 2023
primary completion
Sep 1, 2026
completion
Nov 1, 2026
last updated
Mar 27, 2026
official title
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol